Nephros Acquires Substantially All Assets of GenArraytion, Inc.

July 12, 2021

Nephros, Inc. (Nasdaq: NEPH) acquired substantially all of the assets of GenArraytion, Inc., a Rockville, Maryland-based developer of infectious disease PCR assays and multiplexing technology. The acquisition gives Nephros access to GenArraytion's MultiFLEX bioassays and other proprietary assays, which will be integrated into Nephros' Pathogen Detection Systems platform, and GenArraytion's CEO Dr. R. Paul Schaudies will partner with Nephros' pathogen detection leadership.

Buyers
Nephros, Inc.
Targets
GenArraytion, Inc.
Sellers
GenArraytion, Inc.
Industry
Biotechnology
Location
Maryland, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.